Investors

M Ventures is the strategic, corporate venture capital fund of Merck, investing in Biotechnology and Technology. We cover the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability.

Taiho Ventures is the corporate venture capital arm of Taiho Pharmaceutical, investing in early‑stage biotechnology companies aligned with its focus on oncology and immunology. The fund supports innovative therapeutic platforms with the potential to deliver meaningful advances for patients worldwide.

Epidarex Capital is a transatlantic life‑science venture capital firm focused on building breakthrough companies emerging from leading UK and US research ecosystems. The firm partners early with founders to translate high‑quality science into novel therapeutics addressing significant unmet medical needs.

Oxford Science Enterprises partners with researchers from the University of Oxford to build world‑leading life‑science and technology companies. By combining academic excellence with investment expertise, it helps transform foundational research into impactful, scalable innovations.

Sound Bioventures is a specialist life‑science investor backing clinical and near‑clinical stage companies developing novel therapies for areas of high unmet need. The fund brings hands‑on operational experience to support companies through critical stages of development.

BGF is a long‑term equity investor supporting ambitious UK and Irish companies across multiple sectors, including life sciences. Providing patient capital and strategic support, BGF helps management teams scale sustainably while retaining operational control.